Cargando…

Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors

BACKGROUND: With increased use of immune checkpoint inhibitors (ICIs) among patients with cancer, there is substantial interest in understanding clinical and economic outcomes and management of immune‐related adverse events (irAEs). PATIENTS, MATERIALS, AND METHODS: A retrospective study was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Ying, Kim, Ruth, Yu, Ting, Gayle, Julie A., Wassel, Christina L., Dreyfus, Jill, Phatak, Hemant, George, Saby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Health Outcomes and Economics of Cancer Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571769/ https://www.ncbi.nlm.nih.gov/pubmed/34327774 http://dx.doi.org/10.1002/onco.13918

Ejemplares similares

The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors
por: George, Saby, et al.
Publicado: (2021)

Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer
por: Tan, Ruoding, et al.
Publicado: (2022)

38351 Immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
por: Lucas, Margaret Byrnethew, et al.
Publicado: (2021)

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
por: Heilbroner, Samuel Peter, et al.
Publicado: (2021)

Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective
por: Azoulay, Laurent
Publicado: (2022)

Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment
por: Ludwig, Heinz, et al.
Publicado: (2020)

Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda
por: Kizub, Darya A, et al.
Publicado: (2022)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy
por: Zheng, Ying, et al.
Publicado: (2021)

Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
por: Postmus, Douwe, et al.
Publicado: (2017)

Costs of Cancer Care Across the Disease Continuum
por: Kaye, Deborah R., et al.
Publicado: (2018)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Women Who Are Young, Non‐White, and with Lower Socioeconomic Status Report Higher Financial Toxicity up to 1 Year After Breast Cancer Surgery: A Mixed‐Effects Regression Analysis
por: Politi, Mary C., et al.
Publicado: (2020)

Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta‐Analysis
por: Nielson, Carrie M., et al.
Publicado: (2021)

COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry
por: Borno, Hala T, et al.
Publicado: (2022)

“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management
por: Shickh, Salma, et al.
Publicado: (2022)

Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center
por: Zubiri, Leyre, et al.
Publicado: (2021)

Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID‐19
por: Klein, Isaac A., et al.
Publicado: (2021)

Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act
por: Roth, Michael, et al.
Publicado: (2022)

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States
por: Copher, Ronda, et al.
Publicado: (2022)

Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum
por: Lai-Kwon, Julia, et al.
Publicado: (2022)

Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data
por: Raphael, Jacques, et al.
Publicado: (2022)

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
por: Mitchell, Aaron P, et al.
Publicado: (2022)

The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer
por: Bhatt, Sunil, et al.
Publicado: (2022)

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research
por: Flick, E Dawn, et al.
Publicado: (2023)

Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020
por: Perera, Nirosha D, et al.
Publicado: (2023)

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry
por: Jacob, Aasems, et al.
Publicado: (2021)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
por: Mandala, Mario, et al.
Publicado: (2021)

Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
por: Ghosh, Nilasha, et al.
Publicado: (2022)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
por: Biniakewitz, Matthew D., et al.
Publicado: (2020)

Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
por: Filippini, Daria Maria, et al.
Publicado: (2021)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2019)

Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real‐world evidence from the medicare population
por: Goyal, Ravi K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ga03ufhh81bo8o67n3330e44v